Incremental innovation in biomedical devices is relatively straightforward. Today’s product line gets upgraded to become smaller, faster, cheaper, etc – but there’s little fundamental change to underlying technologies, clinical procedures, health service provision, regulatory requirements, and so on. Unfortunately incremental innovations are insufficient in today’s fast-moving world, and companies recognise the need to invest in more disruptive innovation if they are to protect and grow their businesses.
Identifying and capturing the disruptive opportunities that arise at the interfaces between clinical procedures and research into medicine, biology, engineering and physics is hard for a company and often high risk. The purpose of the Institute for Medical Science & Technology (IMSaT) is to create a dedicated process, organisation and network that binds together researchers from across these disciplines with clinicians, health service providers, biomedical device companies and funders/investors, to identify and rapidly implement mutually beneficial opportunities.
Clinical and commercial needs are the key drivers for IMSaT. Our role is to assemble the right collaborations around the right opportunities and ensure a smooth path from lab to clinic.
.gif)